2022

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Bio Pharma Dive

Hal Barron, a key figure in GSK's efforts to revitalize its drug research, will step down as its top scientist at a time when the company is feeling heat from investors to deliver faster growth

Pharma’s outdated hiring practices

World of DTC Marketing

One of the reasons it’s a job-seekers market because candidates today want more from their employers. They want a good work-life balance and want to be valued as a contributor to the success of their company. We live in an instant gratification world.

HR 230
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDUFA VII: More Changes Coming in the Latest Reauthorization

Camargo

As we noted in a separate blog post , the forthcoming reauthorization of the FDA’s Prescription Drug User Fee Act (PDUFA VII) includes several provisions that are expected to help advance cell and gene therapy products, as well as therapies designed to treat rare diseases.

Feelings of fatigue predict death in older adults

Scienmag

PITTSBURGH, Jan. 24, 2022 – How fatigued certain activities make an older person feel can predict the likelihood death is less than three years away, according to research published today in the Journal of Gerontology: Medical Sciences by University of Pittsburgh epidemiologists.

Lessons in Supply Chain Digitization from PepsiCo and Conagra

Speaker: Craig Weiss, ConAgra Brands; Mari Roberts PepsiCo; and Matt Elenjickal, FourKites

Supply chain digitalization is key to success as market volatility, widespread disruption & stiff competition for consumer dollars puts pressure on every aspect of the supply chain. Register to hear how 2 global brands are accelerating digital transformation and increasing efficiency & automation throughout their operations.

Surprised by a Medical Bill? Here’s What to Do.

Triage Cancer

If you’ve ever been surprised by a medical bill, you’re not alone. An estimated 10 million patients a year receive the shock of unexpectedly high medical bills for emergency or out-of-network care from providers they did not choose.

How digital patient recruitment can reduce enrollment costs in Major Depressive Disorder clinical trials

Clairnes

The post How digital patient recruitment can reduce enrollment costs in Major Depressive Disorder clinical trials appeared first on Clinical Trial Recruitment & Management Services. Blog clinical trial patient recruitment decentralized trials hybrid trials patient centricity regulation changes

More Trending

Abbott CEO Ford showcases new ‘biowearable’ line at CES

Pharma Phorum

US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring.

Stand Up to Cancer research initiative targets pancreatic cancer

Outsourcing Pharma

Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually. Clinical Development

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

BioTech 365

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Charles River Laboratories to Present at J.P. Morgan Healthcare Conference WILMINGTON, Mass.–(BUSINESS –(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc.

77

Protagen, BioAnalytix, and GeneWerk unveil combined CRO business: ProtaGene

BioPharma Reporter

Protagen, BioAnalytix, and GeneWerk this week announced their unified operations and re-brand as ProtaGene, a CRO partner for the biologics and cell and gene therapy developers, from discovery to commercialization. Markets & Regulations

3 Ways End-to-End Visibility Helps Minimize the Risks of Ocean Freight

Download this playbook to learn how end-to-end visibility helps to mitigate risk associated with the ocean freight market.

5 questions facing biotech M&A in 2022

Bio Pharma Dive

Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months

The financial toxicity of treating cancer

World of DTC Marketing

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. after they were diagnosed with metastatic colon cancer. They told the researchers that insurance didn’t protect them from serious money problems.

Drugs 228

New study finds AstraZeneca booster generates higher antibodies against Omicron

Pharma Times

AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria

Trials 104

With $2 million grant, UTA scientist aims to create massive cancer database

Scienmag

University of Texas at Arlington computer scientist Jacob Luber has earned a five-year, $2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to create a database that contains every publicly available cancer dataset from the National Cancer Institute (NCI).

4 Silver Linings of the Chaotic Ocean Freight Market

Speaker: Peter Tirschwell, Chris Stauber, Sarah Barnes Humphrey, and Audrey Ross

Join this webinar exploring the silver linings that have emerged from the chaotic ocean freight market. The discussion will highlight solutions that prioritize digitization and build a more efficient international supply chain. Jan 25 at 10am CT.

Abbott’s New Cardiac Mapping System Gets FDA Clearance for Treatment of Cardiac Arrhythmias

XTalks

Abbott’s new cardiac mapping platform, EnSite X EP System, has received clearance from the US Food and Drug Administration (FDA) for the treatment of cardiac arrhythmias.

Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases

Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.

Bio Pharma Dive

After halting a Phase 3 trial of the drug last year, Roche went digging for more data. What it found led to plans for another trial, but the pharma's hypothesis may rest on shaky ground

Trials 271

AI providing the edge against cancer?

Pharma Phorum

The global R&D pipeline is dominated by potential treatments in oncology and this is also where the investment is flowing.

The Smart Data Revolution: How AB InBev Drives Efficiency with Visibility Data

Speaker: AB InBev and FourKites

Register for our upcoming webinar to learn how leveraging the right data to make quick, well-informed decisions is the key to success in supply chain & logistics. Join FourKites and AB InBev to learn what’s possible with a data-driven supply chain strategy & real-time transportation visibility.

NervGen Pharma sets sights on trial for spinal-cord injury treatment

Outsourcing Pharma

The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern Universityâs Shirley Ryan AbilityLab. Clinical Development

10 clinical trials to watch in the first half of 2022

Bio Pharma Dive

Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around

De-risking cell therapy manufacturing with downstream technology innovation

BioPharma Reporter

Automated cell therapy manufacturing processes could reduce manual intervention and human errors, enabling more robust processes, improved product quality, and lower costs. Downstream Processing

Allogene cleared by FDA to resume 'off the shelf' cancer cell therapy trials

Bio Pharma Dive

A "chromosomal abnormality" that led regulators to halt Allogene's trials was judged to be unrelated to its technology, a finding with important implications for the field of donor-derived cell therapies

Modernizing Pharmaceutical Supply Chains

Speaker: Nimesh Patel, Gregory Demitrack, and Sarah Barnes Humphrey

Register for our upcoming webinar to better understand the state of the pharmaceutical supply chain. FourKites partnered with Accenture to survey supply chain executives working in pharmaceuticals, biotech, cell and gene therapy, medtech, and other related industries.

Can pharma really leverage social media?

World of DTC Marketing

A Mediabistro survey showed that social networks influence more than 40% of people’s health choices. Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharma companies’ content, but is it a good idea?

New blood test can identify presence of cancer

Pharma Times

The test is a technological first in determining the metastatic status of a cancer without using prior insight of the primary cancer presented

104
104

New study sheds light on origins of life on Earth

Scienmag

New Brunswick, N.J. 14, 2022) – Addressing one of the most profoundly unanswered questions in biology, a Rutgers-led team has discovered the structures of proteins that may be responsible for the origins of life in the primordial soup of ancient Earth. Credit: Rutgers New Brunswick, N.J.

5 questions facing gene therapy in 2022

Bio Pharma Dive

As record levels of money pour into gene therapy research, biotechs are under increased pressure to address issues related to safety, delivery and overlapping pipelines

Minimizing Retail Supply Chain Disruptions in 2021 and Beyond

Speaker: Izaac Moran, Customer Success Manager, FourKites; Glenn Koepke, SVP of Customer Success, FourKites; and featuring interviews with supply chain experts from Dollar Tree and Best Buy

Register for our upcoming webinar to see how savvy retailers including Dollar Tree and Best Buy are leveraging real-time visibility across their end-to-end supply chains in creative ways to drive agility and thrive in today’s unpredictable environment.

BioMarin plans return to FDA with updated data on hemophilia gene therapy

Bio Pharma Dive

Two-year results from a Phase 3 study of Roctavian show treatment prevented bleeding, potentially giving BioMarin the data it needs to resubmit an application for approval

JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

Bio Pharma Dive

Pharma executives fielded many questions about their dealmaking intentions on the conference's second day, while Roche outlined its plan to compete against Merck and Bristol Myers in cancer immunotherapy

266
266

Otsuka backs GrayMatters’ digital wearable tech for mental disorders

Pharma Phorum

Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness.

5 questions facing the FDA in 2022

Bio Pharma Dive

If Robert Califf wins Senate confirmation as expected, he will face a lengthy agenda as well as questions on Aduhelm controversy, accelerated approval and agency funding

264
264

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.